Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based
 regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast
 cancer.
In this trial, all the patients will have weekly paclitaxel and cisplatin as neoadjuvant
 chemotherapy for 4 cycles. Patients with Her2 positive tumor will also receive the
 trastuzumab.
Inclusion Criteria:

 1. Women aged ≥18years and ≤70 years

 2. At least on measurable disease according to the Response Evaluation Criteria in Solid
 Tumors (RECIST). Histologically confirmed invasive breast cancer, tumor size ≥2 cm,
 T2-4 N0-2M0

 3. ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER/PR positive is defined as >1%
 stained cells and HER2-positive is defined as immuno-histochemistry (IHC) 3+ or FISH
 ratio ≥ 2.0

 4. No prior systemic or loco-regional treatment of breast cancer

 5. ECOG 0-2

 6. Adequate bone marrow function:WBC≥4.0×109/L, Absolute neutrophil count（ANC）≥1.5×109/L,
 Platelets（PLT）≥100×109/L, Hemoglobin（Hb）≥90g/L;aspartate aminotransferase(AST),Alanine
 aminotransferase (ALT)≤1.5 upper normal limit （UNL）, creatinine≤1.5 UNL,
 bilirubin≤1.5UNL

 7. No obvious main organs dysfunction

 Exclusion Criteria:

 1. Unwilling or unable to use an acceptable method of contraception in 8 weeks (including
 8 weeks) after final dose of test drug

 2. Patient is pregnant or breast feeding

 3. Inflammatory breast cancer and metastatic breast cancer

 4. Any evidence of sense or motor nerve disorders

 5. Patients with medical conditions taht indicate intolerant to neoadjuvant therapy,
 including uncontrolled cardiovascular disease, severe infection

 6. Any concurrent malignancy other than breast cancer

 7. Know severe hypersensitivity to any drugs in this study